2025年10月，国家药监局共批准注册医疗器械产品204个。其中，境内第三类医疗器械产品173个，进口 第三类医疗器械产品10个，进口第二类医疗器械产品21个。 中泰证券认为，国内医疗器械行业持续处于快速发展阶段，短期医保控费和国际形势对医疗器械领域可 能带来负面扰动，但依然看好创新驱动下的进口替代以及全球化发展，当前时间点，预计多重负面影响 正在充分释放，器械板块已进入拐点区间，不同细分拐点节奏或有差异。持续看好：1）国产企业在政 策扶持以及创新驱动下，竞争力不断提升，加速进口替代；2）全球化布局完善，海外市场持续突破的 公司；3）重视AI医疗、脑机接口等主题投资机会。 方正证券认为，医疗器械行业进入调整周期尾声，行业及公司层面边际改善趋势明确，重视底部回升机 会。在医疗行业整顿、招标节奏延迟、集采扩面执行、医保控费等多重压力下，医疗器械板块股价持续 下调；2024年四季度设备更新的加速落地带来短期催化，但由于中标到收入确认存在周期，整体仍处于 底部波动，然而年初以来，该板块已出现一定回升趋势，一方面国家陆续出台政策支持高端创新器械发 展，同时管制价格"内卷"、优化国内招标采购环境，此外设备更新持续驱动采购 ...

Industry Overview - The lithium battery industry is transitioning from simple scale and price competition to a multi-dimensional competition focusing on technological innovation, globalization, integration, and capital strength [2] - Young leaders are emerging as key drivers of industry development and social progress, leveraging their insights and strategic execution capabilities [2] Company Achievements - **Dingsheng New Material**: Achieved a revenue of 19.604 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.29%, and a net profit of 307 million yuan, up 36.61% [6][10] - **GEM Co., Ltd.**: Reported a revenue of 27.498 billion yuan in the first three quarters of 2025, a 10.55% increase, and a net profit of 1.109 billion yuan, up 22.66% [10] - **Tianqi Materials**: Generated a revenue of 10.843 billion yuan in the first three quarters of 2025, a 10.55% increase, with a net profit of 421 million yuan, up 24.33% [13] - **Xian Dao Intelligent**: Recorded a revenue of 10.439 billion yuan in the first three quarters of 2025, a 14.56% increase, and a net profit of 1.186 billion yuan, up 94.97% [16] - **Zhuhai Guanyu**: Achieved a revenue of 10.321 billion yuan in the first three quarters of 2025, a 21.18% increase, and a net profit of 387 million yuan, up 44.37% [20] - **Zhenyu Technology**: Reported a revenue of 6.593 billion yuan in the first three quarters of 2025, a 31.47% increase, and a net profit of 412 million yuan, up 138.93% [24] - **Zhongke Electric**: Generated a revenue of 5.904 billion yuan in the first three quarters of 2025, a 52.03% increase, with a net profit of 402 million yuan, up 118.85% [28] - **Tengyuan Cobalt**: Achieved a revenue of 5.752 billion yuan in the first three quarters of 2025, a 17.65% increase, and a net profit of 751 million yuan, up 21.65% [30] - **Shangtai Technology**: Reported a revenue of 5.506 billion yuan in the first three quarters of 2025, a 52.09% increase, with a net profit of 711 million yuan, up 23.08% [33] - **Zhengli New Energy**: Achieved a revenue of 3.172 billion yuan in the first half of 2025, a 71.94% increase, and a net profit of 220 million yuan, up 269.51% [36]

Core Insights - Jing'an District has significantly increased its participation in the China International Import Expo (CIIE), growing from 16 exhibitors in the first edition to 53 in the eighth, showcasing its strategic focus on attracting investment and promoting economic development [1][2][3] Investment and Business Development - The district has established a "new and old co-prosperity" ecosystem, with companies like Europharma witnessing rapid growth and establishing strong partnerships with the district government [2][3] - The "Investment Jing'an, Win the CIIE" promotional event highlighted the district's commitment to fostering trade and investment, resulting in multiple procurement agreements signed during the expo [3][4] International Brand Engagement - Notable international brands, such as Aster, have chosen Jing'an for their flagship centers, reflecting the district's appeal and investment potential [4][5] - The district's proactive approach in inviting global companies to participate in the CIIE has facilitated a transformation from "investors" to "exhibitors," enhancing their market presence in China [5][6] Innovation and Technology Integration - Jing'an has launched innovative platforms like the "Beauty Hub" and "Meichuang Jingjie," which integrate technology and beauty, aiming to create a comprehensive ecosystem for the beauty industry [12][13] - The collaboration with top-tier resources, including hospitals and research centers, aims to bridge the gap between scientific research and consumer experience in the beauty sector [12][13] Cultural and Economic Synergy - The district's initiatives, such as the "Jing'an International Reception Hall," aim to create a seamless connection between global resources and local enterprises, enhancing the overall business environment [11][12] - Events like the "CIIE" serve as a platform for cultural exchange and economic collaboration, positioning Jing'an as a hub for international business and innovation [10][11]

Core Viewpoint - The medical device sector in China is experiencing a robust growth trajectory, with significant market activity and investment interest, particularly in the context of recent stock performance and market data. Group 1: Market Performance - On November 10, the Shanghai Composite Index saw a rebound, with strong performances in sectors such as food and beverage, beauty care, and pharmaceuticals [1] - The Medical Device Index ETF (159898) rose by 1.75%, with a net subscription of approximately 11 million units, equating to about 6.4 million yuan based on real-time net value [1] Group 2: Industry Growth - According to data from Zhongcheng Shuke, the overall market size of medical device bidding in China grew by 29.8% year-on-year in Q3 2025, indicating a stable growth trend despite a slight deceleration compared to previous quarters [3] - Medical device exports reached $15.224 billion in Q3 2025, marking a year-on-year increase of 4.53%, with medical consumables and equipment exports growing by 3.32% and 8.83%, respectively [3] Group 3: Investment Insights - Zhongtai Securities highlights that the domestic medical device industry is in a rapid development phase, with potential short-term negative impacts from medical insurance cost control and international conditions, but a long-term optimistic outlook driven by innovation and import substitution [3] - The Medical Device Index ETF (159898) tracks the CSI All-Share Medical Device Index, with a composition of 42.42% medical equipment, 33.77% medical consumables, and 23.81% in vitro diagnostics, making it a pure representation of the A-share medical device sector [3] - Over 80% of the constituents of the CSI All-Share Medical Device Index are distributed across the Sci-Tech Innovation Board and the Growth Enterprise Market, highlighting a strong focus on technology-driven growth [3]

Core Insights - Aoyou Dairy Co., Ltd. showcased six major imported brands and 61 products at the 8th China International Import Expo, emphasizing "hardcore innovation, industry empowerment, and internationalization" to highlight the globalization and innovative development of China's dairy industry [2][5] - The company launched several innovative products targeting specific consumer needs, including a series of probiotics for nasal health and a sleep aid probiotic, enhancing its product offerings for different age groups and lifestyles [2][3] Product Innovations - Nutrition Care introduced three new series of probiotics specifically designed for children and adults, marking a significant upgrade from single products to comprehensive health solutions [2] - The new NC sleep probiotic utilizes "endogenous GABA" technology to provide a natural approach to sleep, addressing stress and sleep quality [2] - Aoyou's brand Jiajiaite launched a high-calcium probiotic goat milk powder, featuring 1500mg of calcium and a combination of four probiotics, aimed at supporting bone health and digestion for the elderly [3] Market Position and Trends - Jiajiaite is recognized as the market leader in goat milk powder, with over 2 million positive reviews on JD.com, confirming its advantages in absorption and low sensitivity [4] - A report on infant formula feeding trends was released, revealing key insights into consumer behavior and preferences, which will aid the industry in identifying growth opportunities [3][4] Global Expansion and Strategy - Aoyou is expanding its global presence by establishing a supply chain in key dairy-producing regions like the Netherlands and Australia, with 11 factories worldwide, covering over 60 countries [5] - The company aims to leverage the insights gained from the Import Expo to enhance its research and development efforts and meet the evolving nutritional needs of global consumers [5]

Core Viewpoint - Suzhou Zhongjie Automotive Parts Co., Ltd. has made a significant step in its overseas business expansion by completing the registration of its wholly-owned subsidiary in Hong Kong, which will focus on the import and export of automotive parts and electronic products [1][2]. Group 1 - The company announced that its wholly-owned subsidiary, PXI Technology (Hong Kong) Co., Limited, has been officially registered, marking a substantial advancement in its international business strategy [1]. - The subsidiary's registered capital is HKD 10,000, and it will operate in the import and export of general and automotive parts, as well as electronic products, providing related technical services and consulting [1]. - The establishment of the Hong Kong subsidiary aims to leverage the region's advantages and international platform to enhance the company's global market channels and optimize its supply chain [1][2]. Group 2 - The funding for this investment comes from the company's own resources, ensuring that it will not adversely affect the company's financial status or operational results [2]. - The company has confirmed that this investment does not harm the interests of the company or its shareholders [2].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved steady revenue growth in the first three quarters of 2025, with revenue reaching 781.57 billion yuan, a year-on-year increase of 11.61%, and a net profit attributable to shareholders of 59.77 billion yuan, up 11.67% year-on-year [5] - The company's overseas revenue continues to rise, with export income for the first three quarters of 2025 amounting to 375.94 billion yuan, accounting for 48.10% of total revenue, an increase of 2.30 percentage points year-on-year [5] - The company is enhancing cash flow management, with a net cash flow from operating activities of 56.92 billion yuan for the first three quarters, an increase of 36.48 billion yuan year-on-year [5] - The report forecasts EPS for 2025-2027 to be 0.62 yuan, 0.79 yuan, and 0.89 yuan, corresponding to PE ratios of 17x, 13x, and 12x respectively, maintaining a "Buy" rating [5] Financial Summary - For the first three quarters of 2025, the company reported a gross margin of 22.33%, a decrease of 1.30 percentage points year-on-year, and a net profit margin of 7.78%, an increase of 0.04 percentage points year-on-year [5] - The company’s total market capitalization is 1249.34 billion yuan, with a closing price of 10.63 yuan as of November 3, 2025 [3] - The company’s total revenue projections for 2025-2027 are 1,012.30 billion yuan, 1,129.42 billion yuan, and 1,267.79 billion yuan respectively [6]

人民财讯11月4日电，中泰证券（600918）发布医疗器械板块2025三季报总结研报称，国内医疗器械行 业持续处于快速发展阶段，短期医保控费和国际形式在医疗器械领域可能带来负面扰动，但依然看好创 新驱动下的进口替代以及全球化发展。当前时间点预计多重负面影响正在充分释放，器械板块已进入拐 点区间，不同细分拐点节奏或有差异，建议持续重点关注。投资思路上，持续看好：1.国产企业在政策 扶持以及创新驱动下，竞争力不断提升，加速进口替代；2.看好全球化布局完善，海外市场持续突破的 标的；3.重视AI医疗、脑机接口等主题投资机会。 ...

Core Viewpoint - The domestic medical device industry is in a rapid development phase, with short-term challenges from medical insurance cost control and international conditions, but the outlook remains positive due to innovation-driven import substitution and globalization [1] Group 1: Industry Overview - The medical device sector is expected to enter a turning point, with varying rhythms across different sub-sectors [1] - The revenue of medical device listed companies in the first three quarters of 2025 was 183.35 billion, a year-on-year decrease of 3.90%, while the net profit excluding non-recurring items was 22.70 billion, down 17.70% [2] - The revenue growth rates for different sub-sectors from high to low are high-value consumables (+5.12%), low-value consumables (-0.75%), medical devices (-1.02%), and in vitro diagnostics (-13.94%) [2] Group 2: High-Value Consumables - The high-value consumables sector has entered a post-collection phase, with revenue growth of 5.12% in the first three quarters of 2025 and a net profit increase of 1.18% [4] - In Q3 2025, the revenue growth for high-value consumables was 7.46%, while net profit decreased by 0.76%, indicating relative stability compared to other sectors [4] - The sector is benefiting from increased domestic market share and ongoing innovation and international expansion [4] Group 3: Medical Devices - The medical device sector saw a revenue decline of 1.02% in the first three quarters of 2025, but a significant recovery in Q3 with a revenue increase of 9.99% and a net profit growth of 4.87% [5] - The sector is experiencing a recovery due to improved bidding processes and low base effects, with expectations for continued growth as domestic conditions stabilize [5] Group 4: Low-Value Consumables - The low-value consumables sector experienced a revenue decline of 0.75% in the first three quarters of 2025, with a more significant net profit drop of 21.68% [6] - In Q3 2025, revenue decreased by 2.74% and net profit fell by 21.98%, primarily due to international market fluctuations affecting orders and profitability [6][7] - The sector's growth potential remains tied to international expansion, despite short-term challenges [7] Group 5: In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 13.94% in the first three quarters of 2025, with a net profit drop of 32.20% [7] - The decline is attributed to the implementation of various negative policies, including DRGs and centralized procurement, leading to a drop in both volume and price [7] - Long-term growth prospects are supported by ongoing innovation and international market expansion [7]

Investment Rating - The report maintains an "Overweight" rating for the medical device sector [6] Core Insights - The medical device sector is entering a turning point, driven by innovation and international expansion as key growth drivers [12][29] - The overall revenue for medical device companies in the first three quarters of 2025 was 183.45 billion yuan, a year-on-year decrease of 3.90%, while the net profit excluding non-recurring items was 22.70 billion yuan, down 17.70% [8][15] - Different sub-sectors show significant divergence in performance, with high-value consumables showing a growth of 5.12%, while in vitro diagnostics faced a decline of 13.94% [8][15] Summary by Sections Medical Device Sector Overview - The medical device sector is experiencing a recovery with improved bidding processes and a gradual clearing of high-cost consumables [8][15] - The revenue growth rate for the medical device sector in Q3 2025 was 9.99%, with a net profit growth of 4.87% [9][16] High-Value Consumables - High-value consumables saw a revenue increase of 5.12% in the first three quarters of 2025, with a net profit growth of 1.18% [29] - The sector is stabilizing as it enters the post-collection phase, with significant growth driven by innovation and international expansion [29] Medical Equipment - The medical equipment sector's revenue decreased by 1.02% in the first three quarters of 2025, but showed a positive trend in Q3 with a revenue increase of 9.99% [9][16] - The sector is expected to experience structural differentiation in demand as bidding processes improve [9] Low-Value Consumables - Low-value consumables experienced a revenue decline of 0.75% in the first three quarters of 2025, with a significant drop in net profit by 21.68% [9][16] - The sector's performance is heavily influenced by international market conditions, but there is potential for recovery in Q4 2025 [9] In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 13.94% in the first three quarters of 2025, with net profit down 32.20% [9][16] - The sector is expected to stabilize by the end of 2025 as negative impacts from policies begin to clear [9]